Description
Chemical Identity
Dual Incretin Analog (39-aa) is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with the molecular formula C225H348N48O68 and a molecular weight of approximately 4813.45 Da. Also known as tirzepatide in the research literature, this 39-amino acid synthetic peptide features a C20 fatty diacid side chain attached via a linker at lysine-20, enabling albumin binding for extended pharmacokinetic duration. It was developed by Eli Lilly as a novel dual incretin receptor agonist.
Dual Incretin Analog (39-aa) is also known by the following research designations: LY3298176, Mounjaro, Zepbound.
| Property | Value |
|---|---|
| Molecular Formula | C225H348N48O68 |
| Molecular Weight | 4813.45 Da |
| CAS Number | 2023788-19-2 |
| Sequence | Tyr(Aib)EGTFTSDVSSYLEGQAAKEFIAWLVKGR(C20 fatty diacid via Lys20-linker)-NH2 |
| Research Status | FDA Approved |
Research Overview
Dual Incretin Analog (39-aa), widely known as tirzepatide in published research, has been investigated in one of the largest Phase 3 clinical development programs in metabolic medicine, encompassing the SURPASS (type 2 diabetes) and SURMOUNT (obesity/overweight) trial series. The primary mechanism of action involves dual agonism at both the GIP receptor and GLP-1 receptor, with approximately 5-fold greater potency at GIPR relative to native GIP and complementary GLP-1R activation that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite through hypothalamic signaling.
Key areas of published research include:
- Weight Management: The SURMOUNT-1 Phase 3 trial enrolled 2,539 adults with obesity or overweight and demonstrated unprecedented mean body weight reductions of 15.0%, 19.5%, and 20.9% across ascending dose groups versus 3.1% with placebo at 72 weeks. Up to 36% of participants achieved 25% or more weight loss at the highest dose. SURMOUNT-2 confirmed these findings in the harder-to-treat diabetic population with 12.8-14.7% weight reduction.
- Glycemic Control: The SURPASS-1 trial demonstrated HbA1c reductions of 1.87-2.07% versus 0.04% with placebo in treatment-naive type 2 diabetes patients, with up to 52% of patients achieving HbA1c below the normal threshold of 5.7%. SURPASS-2 demonstrated superiority over a comparator GLP-1 receptor agonist for both HbA1c reduction and weight loss.
- Cardiometabolic Parameters: Across the clinical program, Dual Incretin Analog (39-aa) demonstrated significant improvements in waist circumference, blood pressure, lipid profiles, and inflammatory markers beyond its effects on glycemia and body weight.
This compound received FDA approval as a branded product for type 2 diabetes (May 2022) and chronic weight management (November 2023). The clinical evidence base is extensive, with multiple large-scale Phase 3 randomized controlled trials enrolling thousands of participants.
Specifications
All Dual Incretin Analog (39-aa) supplied by Prescott Bio Canada is manufactured to research-grade standards.
| Specification | Detail |
|---|---|
| Purity | >98% (HPLC) |
| Form | Lyophilized powder |
| Appearance | White to off-white powder |
| Storage (lyophilized) | -20°C, protected from light |
| Storage (reconstituted) | 2-8°C, use within 30 days |
| Solubility | Soluble in bacteriostatic water, sterile water, or normal saline |
Each vial is accompanied by a Certificate of Analysis (COA) documenting purity, identity, and endotoxin testing.
Research Applications
Dual Incretin Analog (39-aa) is supplied exclusively for in vitro and in vivo laboratory research. Published experimental applications include:
- Investigation of dual GIP/GLP-1 receptor signaling synergy in metabolic models
- Assessment of incretin-mediated insulin secretion and glucagon suppression pathways
- Study of central appetite regulation through hypothalamic GLP-1 and GIP receptor activation
- Evaluation of visceral adipose tissue metabolism and cardiometabolic risk factor modification
Researchers should consult the primary literature and institutional review protocols before designing experiments with Dual Incretin Analog (39-aa).
Storage and Handling
Lyophilized powder: Store at -20°C in the original sealed vial, protected from light and moisture. Under these conditions, Dual Incretin Analog (39-aa) maintains stability for up to 24 months.
Reconstituted solution: Reconstitute with bacteriostatic water or sterile water to the desired concentration. Store reconstituted Dual Incretin Analog (39-aa) at 2-8°C and use within 30 days. Avoid repeated freeze-thaw cycles.
Handling precautions: This product is intended for research use only (RUO). Not for human or veterinary diagnostic or therapeutic use. Handle using standard laboratory safety practices including appropriate PPE.